Abstract
Lomitapide is a microsomal triglyceride transfer protein inhibitor licensed as adjunctive therapy for adults with homozygous familial hypercholesterolemia (HoFH). LOWER is an international, observational registry assessing the long-term safety and effectiveness of lomitapide. This analysis examines
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
